The resubmission for Dupixent includes new data in pediatric patients with chronic spontaneous urticaria.
FDA Accepts Resubmission of Supplemental Biologics License Application for Dupixent for Chronic Spontaneous Urticaria in Patients Under 12
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours